The biohealth corporation WSI is in the process of initiating sales and unit price contracts with over 50 advanced general hospitals and major university hospitals, including Seoul National University Hospital, for the supply of central venous catheters (CVC) and peripherally inserted central catheters (PICC), as of 24th.
WSI noted that it has actively undertaken sales and marketing activities related to the main uses of CVC and PICC at various academic conferences, including the Korean Interventional Radiology Society's autumn academic conference, the Korean Society of Emergency Medicine's autumn academic conference, and the Korean Society of Anesthesiology and Pain Medicine's international academic conference. Additionally, it has completed territorial distribution contracts with sales agencies across eight regions.
According to the company, WSI has been expanding sales and increasing market share since starting sales of CVC and PICC in collaboration with KIMAL in August. KIMAL is a medical device company specializing in the production of vascular access devices and medical packages, headquartered in the United Kingdom.
WSI's CVC and PICC item sales are projected to exceed 3 billion won starting next year. A WSI representative said, 'Once the registration and launch of the Altius HF product are confirmed, market share will increase and performance growth will accelerate.'
It has also been reported that the surgical micro-robot technology development of its subsidiary, Easy MediBot, in the field of bio-robotics is proceeding smoothly. Research and development has been completed under a project led by the Ministry of Health and Welfare in collaboration with the Department of Obstetrics and Gynecology of Seoul National University and the Korea Aerospace University, and the technology and patents have been fully transferred to WSI. WSI is currently preparing for medical device permit registration for prototype development and launch in 2025.
Additionally, Easy MediBot has signed an exclusive supply contract for cardiovascular medical devices with Chinese heart disease medical device corporation Lifetech Scientific. WSI has submitted the product approval documents for Lifetech Scientific's heart disease treatment device 'KONAR-MF,' which is expected to launch in the second half of next year. KONAR-MF is a device for percutaneous closure of ventricular septal defects, one of the congenital heart defects.
A WSI representative said, 'The development of surgical robots in the medical field, which our subsidiary Easy MediBot is focusing on, is also progressing smoothly,' adding that a prototype will be showcased to developers and investors in the first half of next year for launch.